<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00638326</url>
  </required_header>
  <id_info>
    <org_study_id>Pecs-001</org_study_id>
    <nct_id>NCT00638326</nct_id>
  </id_info>
  <brief_title>Doubling the Maintenance Dose of Clopidogrel in Patients With High On-Clopidogrel Platelet Reactivity</brief_title>
  <acronym>DOSER</acronym>
  <official_title>150 mg Maintenance Dose of Clopidogrel in Patients With High On-Clopidogrel Platelet Reactivity After Elective Percutaneous Coronary Intervention</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Pecs</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Pecs</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to determine whether administration of 150 mg clopidogrel is
      effective in reducing the one-year incidence of thromboischemic events in patients with high
      on-clopidogrel platelet reactivity compared to 75 mg clopidogrel after elective percutaneous
      coronary intervention.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Greater differences between randomized patients than previously anticipated
  </why_stopped>
  <start_date>March 2008</start_date>
  <completion_date type="Actual">March 2010</completion_date>
  <primary_completion_date type="Actual">September 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cardiac death or non-fatal myocardial infarction or ischemia-driven target vessel revascularisation.</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Academic Research Consortium (ARC) definite / probable stent thrombosis</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac death and non-fatal myocardial infarction</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac death or non-fatal myocardial infarction or ischemia-driven target vessel revascularisation or TIMI major/minor bleeding</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>5 microM ADP-induced platelet aggregation assessed by light transmission aggregometer</measure>
    <time_frame>25 +/-2 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>VASP-PRI</measure>
    <time_frame>25 +/-2 days</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Stable Angina Pectoris</condition>
  <condition>Ad Hoc Percutaneous Coronary Intervention</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Patients who show adequate response to 600 mg loading dose of clopidogrel and receive standard 1x75 mg clopidogrel</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients who show suboptimal response to 600 mg loading dose of clopidogrel and receive 1x150 mg clopidogrel for 28 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients who show suboptimal response to 600 mg loading dose of clopidogrel and receive 1x75 mg clopidogrel</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>clopidogrel</intervention_name>
    <description>150 mg maintenance dose (2 capsules of 75 mg clopidogrel) for 28 days followed by standard 75 mg clopidogrel for one year</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>clopidogrel plus placebo</intervention_name>
    <description>75 mg maintenance dose (one capsule of 75 mg clopidogrel and one capsule placebo) for 28 days followed by standard 75 mg clopidogrel for one year</description>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Clopidogrel-naïve stable angina pectoris (CCS I-III)

          -  Coronary angiography that reveals significant DE NOVO coronary stenosis (diameter
             stenosis greater than 50% in two independent projections) feasible for ad hoc stent
             implantation

        Exclusion Criteria:

          -  Acute coronary syndrome (STEMI, NSTEMI or unstable angina)

          -  Administration of clopidogrel/ticlopidine/coumarin in the past 6 weeks

          -  Contraindication to antiplatelet therapy

          -  Significant LM stenosis

          -  PCI due to instent restenosis

          -  Lesion located in bypass grafts

          -  Stroke in past one year

          -  Reduced life expectancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ivan G Horvath, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Heart Institute, University of Pécs, HUNGARY</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Daniel Aradi, MD</last_name>
    <role>Study Director</role>
    <affiliation>Heart Institute, University of Pécs, HUNGARY</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Andras Komocsi, MD PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Heart Institute, University of Pécs, HUNGARY</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Heart Institute, University of Pécs, Dept. of Interventional Cardiology</name>
      <address>
        <city>Pécs</city>
        <zip>7624</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Hungary</country>
  </location_countries>
  <verification_date>March 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 11, 2008</study_first_submitted>
  <study_first_submitted_qc>March 11, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 19, 2008</study_first_posted>
  <last_update_submitted>March 20, 2010</last_update_submitted>
  <last_update_submitted_qc>March 20, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 23, 2010</last_update_posted>
  <responsible_party>
    <name_title>Ivan G. Horvath</name_title>
    <organization>Heart Institute, University of Pécs, Dept. of Interventional Cardiology</organization>
  </responsible_party>
  <keyword>Clopidogrel, thrombosis, Percutaneous Transluminal Coronary Angioplasty, stents</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Angina Pectoris</mesh_term>
    <mesh_term>Angina, Stable</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Clopidogrel</mesh_term>
    <mesh_term>Ticlopidine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

